| Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma G Lamberti, E Andrini, M Sisi, A Rizzo, C Parisi, A Di Federico, ... Critical reviews in oncology/hematology 156, 103119, 2020 | 132 | 2020 |
| Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand? A Rizzo, AD Ricci, A Di Federico, G Frega, A Palloni, S Tavolari, G Brandi Frontiers in oncology 11, 803133, 2021 | 97 | 2021 |
| Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? A Rizzo, V Dadduzio, AD Ricci, F Massari, A Di Federico, ... Expert opinion on investigational drugs 31 (4), 371-378, 2022 | 95 | 2022 |
| Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials A Di Federico, A Rizzo, R Carloni, A De Giglio, R Bruno, D Ricci, G Brandi Expert Opinion on Investigational Drugs 31 (4), 361-369, 2022 | 90 | 2022 |
| Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects A Rizzo, AD Ricci, L Lanotte, L Lombardi, A Di Federico, G Brandi, ... Expert opinion on investigational drugs 31 (6), 557-565, 2022 | 80 | 2022 |
| STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? A Di Federico, A De Giglio, C Parisi, F Gelsomino European Journal of Cancer 157, 108-113, 2021 | 75 | 2021 |
| Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes A Di Federico, M Mosca, R Pagani, R Carloni, G Frega, A De Giglio, ... Cancers 14 (10), 2429, 2022 | 70 | 2022 |
| The landscape of immunotherapy in advanced NSCLC: Driving beyond PD-1/PD-L1 inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, vaccines) A De Giglio, A Di Federico, G Nuvola, C Deiana, F Gelsomino Current oncology reports 23, 1-15, 2021 | 66 | 2021 |
| Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC JV Alessi, A Elkrief, B Ricciuti, X Wang, A Cortellini, VR Vaz, G Lamberti, ... Journal of Thoracic Oncology 18 (6), 731-743, 2023 | 59 | 2023 |
| Hacking pancreatic cancer: present and future of personalized medicine A Di Federico, V Tateo, C Parisi, F Formica, R Carloni, G Frega, A Rizzo, ... Pharmaceuticals 14 (7), 677, 2021 | 40 | 2021 |
| Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer B Ricciuti, G Lamberti, SR Puchala, NR Mahadevan, JR Lin, JV Alessi, ... Journal of Clinical Oncology 42 (11), 1311-1321, 2024 | 37 | 2024 |
| Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients–a single centre experience FG Dall’Olio, N Conci, G Rossi, M Fiorentino, A De Giglio, G Grilli, ... Lung Cancer 149, 5-9, 2020 | 37 | 2020 |
| Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication G Lamberti, E Andrini, M Sisi, AD Federico, B Ricciuti Future Oncology 16 (23), 1751-1766, 2020 | 33 | 2020 |
| PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression≥ 50%: selecting the best strategy A Di Federico, A De Giglio, C Parisi, F Gelsomino, A Ardizzoni Critical Reviews in Oncology/Hematology 160, 103302, 2021 | 25 | 2021 |
| Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysis A Di Federico, A De Giglio, F Gelsomino, F Sperandi, B Melotti, ... JNCI: Journal of the National Cancer Institute 115 (1), 29-42, 2023 | 22 | 2023 |
| Peripheral nervous system adverse events associated with immune checkpoint inhibitors S Rossi, F Gelsomino, R Rinaldi, L Muccioli, F Comito, A Di Federico, ... Journal of Neurology 270 (6), 2975-2986, 2023 | 21 | 2023 |
| Targeting BRAF-mutant biliary tract cancer: recent advances and future challenges A Rizzo, AD Federico, AD Ricci, G Frega, A Palloni, R Pagani, S Tavolari, ... Cancer Control 27 (1), 1073274820983013, 2020 | 19 | 2020 |
| Clinical utility and application of liquid biopsy genotyping in lung cancer: a comprehensive review MC Nigro, PV Marchese, C Deiana, C Casadio, L Galvani, A Di Federico, ... Lung Cancer: Targets and Therapy, 11-25, 2023 | 18 | 2023 |
| Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond M Mosca, MC Nigro, R Pagani, A De Giglio, A Di Federico Biomolecules 13 (12), 1803, 2023 | 18 | 2023 |
| Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC JV Alessi, X Wang, A Elkrief, B Ricciuti, YY Li, H Gupta, LF Spurr, H Rizvi, ... Journal of Thoracic Oncology 18 (11), 1524-1537, 2023 | 18 | 2023 |